Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 6/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11086770 | 0.74 | — | — | |
| SCHEMBL18894611 | 0.72 | HTR2C (0.39) | — | |
| SCHEMBL4637369 | 0.71 | — | — | |
| SCHEMBL6431503 | 0.63 | SRD5A2 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL6431907 | 0.63 | SRD5A2 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL6435004 | 0.63 | SRD5A2 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL10515993 | 0.63 | — | — | |
| SCHEMBL10522115 | 0.62 | CTDSP1 (0.46) | CTDSP1ALDH1A1SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL3435214 | 0.61 | — | — | |
| SCHEMBL4471221 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220064123-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | UNIV YALE (US) | 2022-03-03 | — | — | US | disclosed |
| US-11142503-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200392086-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | UNIV YALE (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3434669-B1 | INTERMEDIATE COMPOUNDS UTILIZABLE IN SYNTHESIS OF (-) HUPERZINE AND PROCESS FOR OBTAIN ONE OF THESE INTERMEDIATE COMPOUNDS | UNIV YALE (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10781179-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200223860-A1 | THE TOTAL SYNTHESIS OF GLUCOSEPANE AND RELATED CHEMICAL REACTIONS, COMPOUNDS AND COMPOSITIONS AND OBTAINED THEREFROM AND METHODS OF TREATMENT | UNIV YALE (US) | 2020-07-16 | — | — | US | disclosed |
| US-10457643-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3434669-A1 | INTERMEDIATE COMPOUNDS UTILIZABLE IN SYNTHESIS OF (-) HUPERZINE AND PROCESS FOR OBTAIN ONE OF THESE INTERMEDIATE COMPOUNDS | Yale University (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180291031-A1 | TOTAL SYNTHESIS OF GLUCOSEPANE AND COMPOUNDS OBTAINED THEREFROM | YALE UNIVERSITY (US) | 2018-10-11 | — | — | US | disclosed |
| US-20150087886-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2015-03-26 | — | — | US | disclosed |
| US-8889689-B2 | Bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | STC.UNM (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140248268-A1 | Rab7 GTPase Inhibitors and Related Methods of Treatment | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-09-04 | — | — | US | disclosed |
| US-8765803-B1 | Rab7 GTPase inhibitors and related methods of treatment | STC.UNM (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2681199-A1 | (--)- HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | Yale University (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20120302582-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-11-29 | — | — | US | disclosed |
| WO-2012121863-A1 | (--)- HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | YALE UNIVERSITY (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | disclosed |
| WO-2011094260-A2 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | STC. UNM (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781179-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | CTDSP1 3051/4885SRD5A1 1448/4885SRD5A2 1025/4885 |
| US-20120302582-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | POLN, MED16, POLR2E | CTDSP1 109/4885SRD5A1 3790/4885SRD5A2 4001/4885 |
| US-11142503-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | CTDSP1 3051/4885SRD5A1 1448/4885SRD5A2 1025/4885 |
| US-20200392086-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | CHRNA5, HTR2A, HTT | CTDSP1 3033/4885SRD5A1 1458/4885SRD5A2 1032/4885 |
| US-20150087886-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | POLN, MED16, GMNN | CTDSP1 127/4885SRD5A1 3622/4885SRD5A2 3975/4885 |
| US-20140248268-A1 | Rab7 GTPase Inhibitors and Related Methods of Treatment | RAB7A, RAB5B, RAB1A | CTDSP1 3905/4885SRD5A1 3909/4885SRD5A2 4177/4885 |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | CTDSP1 562/4885SRD5A1 3319/4885SRD5A2 3674/4885 |
| US-10457643-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | CTDSP1 3051/4885SRD5A1 1448/4885SRD5A2 1025/4885 |
| US-20200223860-A1 | THE TOTAL SYNTHESIS OF GLUCOSEPANE AND RELATED CHEMICAL REACTIONS, COMPOUNDS AND COMPOSITIONS AND OBTAINED THEREFROM AND METHODS OF TREATMENT | PTMS, AGER, GALE | CTDSP1 3671/4885SRD5A1 3969/4885SRD5A2 4236/4885 |
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | CTDSP1 3051/4885SRD5A1 1448/4885SRD5A2 1025/4885 |
| US-20220064123-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | CHRNA5, HTR2A, HTT | CTDSP1 3033/4885SRD5A1 1458/4885SRD5A2 1032/4885 |
| US-20180291031-A1 | TOTAL SYNTHESIS OF GLUCOSEPANE AND COMPOUNDS OBTAINED THEREFROM | PTMS, GALE, AGER | CTDSP1 3552/4885SRD5A1 3949/4885SRD5A2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.